Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07339943 | Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness(MicroUSgFLA) | recruiting | N/A | 7 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07377006 | Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer | recruiting | N/A | 108 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07378670 | DEfeating PEnile CAncer-2(DEPECA-2) | recruiting | N/A | 80 | University Hospital TuebingenOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07510906 | Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer(P-PET) | not yet recruiting | N/A | 25 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07657806 | DEC003M in Prostate Cancer | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07729150 | Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes(ReduceHEAT) | recruiting | N/A | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841041 | Effects of Testicular Self-Examination Training Methods on Students' Behaviors and Health Beliefs | completed | N/A | 122 | Yeditepe UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03085043 | Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer | active not recruiting | N/A | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05241860 | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)(A-DREAM) | active not recruiting | Phase 2 | 79 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05520255 | 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028 | recruiting | Phase 3 | 2,800 | University of AlbertaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06836726 | Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer(EVO) | not yet recruiting | Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | recruiting | Phase 1 | 36 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 320 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 60 | Flare Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838753 | A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs(STEPDOWNmHSPC) | not yet recruiting | Phase 2 | 170 | Kokilaben Dheerubhai Ambani Hospital and ResearchUNKNOWN | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04219059 | MR Radiomic Features in Prostate Cancer | completed | — | 200 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT06534918 | Precise Oncology Interventions in Nutrition and Training (OnPoint)(OnPoint) | recruiting | N/A | 306 | University of MiamiOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06926283 | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830212 | Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study | not yet recruiting | Phase 2 | 50 | Yong HeOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00034424 | Cause of Familial Testicular Cancer | completed | — | 749 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00352924 | Agriculture Health Study | active not recruiting | — | 89,655 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00923221 | Collection of Blood From Patients With Prostate Cancer | recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02594202 | Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue | recruiting | — | 3,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05588128 | Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL | recruiting | — | 350 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06202820 | CV CARE: CardioVascular Care in PC Patients | recruiting | N/A | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06780670 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy(PSMAcTION) | recruiting | Phase 2 / Phase 3 | 443 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06855277 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC(AcTFirst) | recruiting | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT06894511 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC(PSMAndARPI) | active not recruiting | Phase 2 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Juri Biosciences, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832617 | Protoacoustic Imaging For 3D Mapping | recruiting | — | 24 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03237026 | Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients | recruiting | — | 360 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04104893 | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation(CHOMP) | active not recruiting | Phase 2 | 40 | VA Office of Research and DevelopmentFED | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04335682 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide(ARACOG) | completed | Phase 2 | 111 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | terminated | Phase 1 | 3 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06594887 | Rectal Spacers Use in Prostate Cancer Radiation Therapy | active not recruiting | N/A | 50 | Princeton ProCure management, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07234981 | PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer | recruiting | Phase 2 | 54 | University of NebraskaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07518888 | Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer(ESCAPE) | not yet recruiting | N/A | 49 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830511 | RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial(RIDDLELN) | not yet recruiting | Phase 3 | 206 | Robert FörsterOTHER | 0 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials